United States was Autolus Therapeutics’s largest region in fiscal 2025, bringing in $74.32M of $74.37M (100%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $1.35M | — | $74.32M |
| Europe | — | $10.12M | $50.00K |
| United Kingdom | $346.00K | — | — |
| Total | $1.70M | $10.12M | $74.37M |
Autolus Therapeutics brought in $74.37M from its two regions in fiscal 2025, the year ended December 31, 2025. Autolus Therapeutics regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $10.12M. United States was the largest at $74.32M (99.9%), ahead of Europe at $50.00K (0.1%).
Autolus Therapeutics began breaking out Europe in fiscal 2024, when it brought in $10.12M. Autolus Therapeutics stopped reporting United Kingdom as a separate region after fiscal 2023, when it brought in $346.00K.
Product Revenue, Net was Autolus Therapeutics’s largest product and service line in fiscal 2025, bringing in $74.32M of $76.41M (97%).
| Product and Service | FY 2018 | FY 2018 | FY 2019 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue, Net | — | — | — | — | — | — | — | — | $74.32M | ||||||
| License | — | $2.37M | — | $1.20M | $1.29M | $406.00K | $1.35M | $10.12M | $2.09M | ||||||
| Grant | $166.00K | — | $166.00K | — | — | — | — | — | — | ||||||
| Total | $166.00K | $2.37M | $166.00K | $1.20M | $1.29M | $406.00K | $1.35M | $10.12M | $76.41M |
Autolus Therapeutics brought in $76.41M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Autolus Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $10.12M. Product Revenue, Net was the largest at $74.32M (97.3%), ahead of License at $2.09M (2.7%).
Autolus Therapeutics began breaking out Product Revenue, Net in fiscal 2025, when it brought in $74.32M. Autolus Therapeutics stopped reporting Grant as a separate line after fiscal 2022, when it brought in $166.00K.
Autolus Therapeutics (AUTL) reports its revenue by geography and by product and service. In fiscal 2025, United States was its largest region, bringing in $74.32M (99.9% of the total), followed by Europe at $50.00K (0.1%).
United States was Autolus Therapeutics' largest region in fiscal 2025, bringing in $74.32M, or 99.9% of the $74.37M total across its two regions.
Product Revenue, Net was Autolus Therapeutics' largest product and service line in fiscal 2025, bringing in $74.32M, or 97.3% of the $76.41M total across its two product and service lines.
Every figure comes from Autolus Therapeutics' annual financial filings, as reported. Each line keeps the name Autolus Therapeutics gives it, and years follow its fiscal calendar.
Autolus Therapeutics' revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.